Clinical and Translational Research
Copyright ©The Author(s) 2024.
World J Clin Cases. Jul 6, 2024; 12(19): 3890-3897
Published online Jul 6, 2024. doi: 10.12998/wjcc.v12.i19.3890
Table 1 Patient characteristics for the primary analysis
 Fexuprazan 10 mg BID[3], before matching (n = 102)Fexuprazan 10 mg BID[3], after matching (n = 44.51)Rebamipide 100 mg TID[4] (n = 225)
Age, yr46.4-46.8
Male35.341.841.8
Body mass index (kg/m2)23.72424
SmokingNon-smoker77.577.377.3
Smoker11.814.214.2
Alcohol drinkingNon-drinker28.4-39.1
Drinker57.8-57.3
Erosion2 (1-2 erosions)56.934.734.7
3 (3-5 erosions)24.533.333.3
4 (≥ 6 erosions)18.63232
Edema1 (none)29.442.742.7
Redness1 (none)47.116.916.9
2 (mild)38.25252
3 (moderate)10.827.127.1
Hemorrhage1 (none)83.360.460.4
2 (1 lesion)8.816.416.4
3 (2-5 lesions)5.916.916.9
4 (6-10 lesions)14.94.9
Patient-assessed symptom score20.5-9.1